74 patents
Page 4 of 4
Utility
Capsule Formulations
3 Jun 20
Manmohan Reddy LELETI, Jay P. POWERS
Filed: 26 Nov 19
Utility
Heteroaryl Sulfonamides and CCR2/CCR9
13 May 20
Compounds are provided that act as potent antagonists of the CCR2 receptor.
Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M.K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
Filed: 9 Jan 20
Utility
Inhibitors of CXCR2
6 May 20
Xi CHEN, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
Filed: 11 Jun 19
Utility
Substituted Tetrahydropyrans As CCR2 Modulators
22 Apr 20
Junfa FAN, Jaroslaw Kalisiak, Rebecca M. LUI, Venkat Reddy MALI, Jeffrey P. McMahon, Jay P. Powers, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
Filed: 22 Sep 19
Utility
2-OXINDOLE Compounds
22 Apr 20
Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
Filed: 28 Jul 19
Utility
Substituted Anilines As CCR(4) Antagonists
22 Apr 20
Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
Trevor T. CHARVAT, Junfa FAN, Christopher W. LANGE, Manmohan Reddy LELETI, Yandong LI, Venkat Reddy MALI, Jeffrey P. McMAHON, Jay POWERS, Sreenivas PUNNA, Ju YANG
Filed: 29 Jul 19
Utility
Compositions and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor Type 9 (CCR9) and ANTI-ALPHA4BETA7 Integrin Blocking Antibodies
15 Apr 20
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof.
Karen EBSWORTH, Yu WANG, Yibin ZENG, Penglie ZHANG, Joanne TAN
Filed: 8 Dec 19
Utility
CXCR7 Antagonists
25 Mar 20
Junfa FAN, Antoni KRASINSKI, Christopher W. LANGE, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
Filed: 8 Apr 19
Utility
Combination Therapy Using C-C Chemokine Receptor 4 (CCR4) Antagonists and One or More Immune Checkpoint Inhibitors
4 Mar 20
The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
Shijie LI, Venkat Reddy MALI, Rajinder SINGH, Ju YANG, Penglie ZHANG
Filed: 27 Aug 19
Utility
Macrocyclic Immunomodulators
19 Feb 20
Viengkham MALATHONG, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Penglie ZHANG
Filed: 7 Jul 19
Utility
Modulators of Chemokine Receptors
5 Feb 20
Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Manmohan Reddy LELETI, Venkat MALI, Jeffrey McMAHON, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
Filed: 15 May 19
Utility
DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
11 Dec 19
Jun DENG, Petrus BEKKER, Jan HILLSON
Filed: 5 Jun 19
Utility
Methods of Treating Pancreatic Cancer
20 Nov 19
The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
Petrus Bekker, Shichang Miao, Israel Charo, Tom Schall
Filed: 30 Jul 19
Utility
PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
2 Oct 19
Pingchen FAN, Rebecca M. LUI, Rajinder SINGH, Venkat Reddy MALI, Yibin ZENG, Penglie ZHANG
Filed: 31 Mar 19